Nkarta NKTX 深 沪
等待开盘 11-03 09:30:00 美东时间
2.11
+0.030
+1.44%
华盛通- 最 高2.1795
- 今 开2.08
- 成交量 90.59万股
- 最 低 2.07
- 昨 收 2.08
- 总市值 1.50亿
- 52周最高 3.8099
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 1.31
- 委 比 -95.35%
- 总股本 7102.45万
- 历史最高 79.16
- 量 比 0.67
- 振 幅 5.26%
- 历史最低 1.28
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nkarta to Participate in November Investor Conferences
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in two investor conferences in November 2025. The company will attend the Stifel 2025 Healthcare Conference on November 12 at 10:40 a.m. ET and TD Cowen’s Immunology & Inflammation Summit on November 13 at 5 p.m. ET. A simultaneous webcast will be available on Nkarta’s website, www.nkartatx.com, with a rep...
10-30 17:14
Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models
Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in
10-22 22:14
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
<p>Nkarta, Inc. announced it will present clinical and preclinical data on its investigational NKX019 therapy at the ACR Convergence 2025 meeting in Chicago. NKX019, an allogeneic CD19-targeting CAR-NK cell therapy, demonstrates robust depletion of pathogenic B cells and potential for treating B-cell driven autoimmune diseases. The poster presentation, titled "NKX019... in hematological malignancy and models of autoimmune disease," will be presen...
10-22 14:07
Nkarta to Participate in a September Investor Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, featuring a fireside chat at 8:30 a.m. ET. The event will be webcast live and available for replay on Nkarta’s website for 90 days. Nkarta develops allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases, utilizing cell expansion, cryopreservation, engineering technologies, and CRISPR-based ge...
09-02 12:01
Nkarta shares are trading higher after the company reported better-than-expected Q2 financial results.
Nkarta shares are trading higher after the company reported better-than-expecte...
08-13 22:44
Needham Reiterates Buy on Nkarta, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $10 price target.
08-13 18:04
Nkarta Q2 EPS $(0.31) Beats $(0.37) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 15.3 percent. This is a 8.82 percent increase over losses of $(0.34) per share from the same
08-13 04:16
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Nkarta reported Q2 2025 financial results with $334M cash balance, supporting operations into 2029. NKX019 clinical trials in autoimmune diseases are enrolling patients, with preliminary data expected in H2 2025. Shawn Rose, M.D., was appointed CMO, adding expertise in autoimmune conditions. The company remains focused on advancing NK cell therapies for unmet needs in autoimmune diseases.
08-12 20:01
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered NK cell therapies, will participate in the H.C. Wainwright "HCW@Home" Series. The event will feature a fireside chat on July 30, 2025, at 11:00 a.m. ET, and registration is available via the provided link. Nkarta is advancing allogeneic NK cell therapies for autoimmune diseases using cell engineering and genome-editing technologies. The company aims to develop accessib...
07-23 12:01
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
